Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
More to come on
Huge funding and on this soon....
On the progress of vaccines and therapeutics, Trump said: “I think you’re gong to have a big surprise, a beautiful surprise, sooner than anybody would think.”
From the quote below in the PR, the 2 participants were not removed from the study completely is my take. Could these 2 participants have been used for Therapeutic analysis instead. We know they were excluded in the immune analysis at the study entry.
"One participant in the 1.0 mg dose cohort and
two participants in the 2.0 mg dose cohort were excluded in the immune analyses as they tested positive for
COVID-19 immune responses at study entry, indicating prior infection.
Funding is Coming Folks
Now OWS
The MM`s could run this down to $26 for the shorts to cover. Bad day to use sell stops with bigger news coming.
I would not be surprised if we close at $36 today.
AdamS007, where art thou
Do you think we get part 2 after P1 results
Everyone should think about this.... whats more important to the world economy right now...Tesla at $1009.35/share or INO at $31.69/share.
The World Economy has been disseminated by this China Virus
How many Trillions of damage to the World Economy?
Pick up more shares at 29.7
Should be released anytime before July 1st, Less than 36 hours from now
The announcement on progress of vaccines could be coming this week as well
On the progress of vaccines and therapeutics, Trump said: “I think you’re gong to have a big surprise, a beautiful surprise, sooner than anybody would think.”
He didn`t sell after the big move, he sold 19,467 at $14.70 on June 22nd
He still has over 60,000 shares left
Common Stock 6/22/2020 S(1)
19467 D $14.70 63433 D
Kate Broderick Presentation to International Society for Vaccines
scroll to min mark 3:00 when she starts her presentation.
First viewed June 26th
Department of Defense Spend Plan...Page 10
Medical Countermeasures, $406.8 Million
Research, Development, Test & Evaluation, Defense-Wide, $11.8 Million
Defense Health Program, $395.0 Million
Funds are required to procure vaccines, anti-virals, and public health surveillance, including:
Procurement of vaccines -- assumes procurement of approximately 7.5 million doses at approximately $19 per dose.
Covered population assumes approximately 6.8 million Defense Health Program beneficiaries (Active Duty (AD), AD Family Members, non-Medicare eligible retirees and retiree family members) and an additional 700 thousand doses for DoD civilians.
https://pandemic.oversight.gov/sites/default/files/2020-06/DoD%20CARES%20Act%20Spend%20Plan%20-%20Final.pdf
Active and reserve Military Personnel totals 2 million.
Their Families will have to be protected as well.....4 to 6 million
Page 2
The Department’s CARES Act spend plan fully funds the most immediate, critical COVID-19 response requirements in accordance with the following mission priorities (focused on the top two priorities for the spend plan): 1. Protect our military and civilian personnel and their families
2. Safeguard our national security capabilities
3. Support the President’s whole-of-nation response to the pandemic
https://pandemic.oversight.gov/sites/default/files/2020-06/DoD%20CARES%20Act%20Spend%20Plan%20-%20Final.pdf
Wow....could this be a slice of Part 2 that`s coming.
"The vaccine could be used in a phase 2 context to protect DoD personnel, healthcare workers or others at high risk for COVID-19 exposure.”
Page 8...Diagnostics and Medical Research $1,642.7 Billion
Funds are required for the development of vaccines and antivirals, 24/7 lab operations, procurement of diagnostic tests, and research activities. Investment across all U.S. government partners is necessary to deliver effective treatment and prevention products that will protect citizens and preserve the readiness and lethality of our DOD service members in the least amount of time. Emerging infectious diseases like COVID-19 are why a global network of military infectious disease surveillance laboratories exist around the world and military medical research is a force multiplier designed to support the service member and the public. Vaccines are the primary tool for prevention of COVID-19. DoD is supporting three vaccine candidates across the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), U.S. Army Medical Research and Development Command (USAMRDC), and Navy Medical Research Center (NMRC).
The current CARES Act spend plan:
Supports the discovery of new vaccine candidates in DoD laboratories and in conjunction with external partners, initial testing in animals, and early clinical studies to determine if products are safe and if they work.
Includes the animal model work needed to support the development of those products. Animal models help accelerate development by providing early information of vaccine safety and effectiveness.
Operation Warp Speed Baby!!!
My last post today, check back tomorrow.
Miami Gent….quit telling the Board the Cellectra Device is an electrocution device, that’s Impossible. A 1.5vDC(Direct Current) AA battery will not even shock you under the wettest conditions. The human body typically has a resistance to current of 100,000 to 500,000 ohms. The current would be a minimum 0.000015 amps @ 1.5v. It takes 0.1 amps or 100mA to kill a person with enough voltage. The voltage has to be high enough to push the current 0.1 amps through the body. A wall outlet in your house has enough voltage @ 120vAC (Alternating current) which can provide enough voltage under the right conditions to overcome your body resistance to kill you, meaning if you are grounded enough while touching a live conductor. AC Voltage can kill, you can play will low DC voltage, i.e. a 1.5vdc battery.
My background……32 years in Power Generation…. Coal Electrical Generating Stations….Natural Gas Combustion Turbine/Steam Turbine Generation…….DCS Controls Technician/ Industrial Electrical, Instrumentation/ High Voltage Switchyard Electrical. Voltage levels 24vDC control voltage to 345kv AC Transmission Voltage.
On the progress of vaccines and therapeutics, Trump said: “I think you’re gong to have a big surprise, a beautiful surprise, sooner than anybody would think.”
Did anyone catch this Wednesday.
President Trump said he would welcome getting Poland involved in a potential vaccine for Covid-19 and predicted there will be a “beautiful surprise, sooner than anybody would think.”
If Part 2 for July is not the Phase 1 results, this thing will be at $50 when Part 2 comes out. Phase 1 results are probably already prized into the stock now.
Feed The Beast!!!!
Market watch interviewed Dr. Kim after Fauci testimony
https://www.marketwatch.com/story/race-for-a-covid-19-vaccine-has-drug-makers-scaling-up-manufacturing-before-one-is-developed-2020-06-25?mod=mw_quote_news
Release The Beast, Winter is Coming Shorties
The Perfect Storm to drown the shorts would be to
Release P1 Results tomorrow, then release the Part 2 entrée Monday morning
This Stock is in Beast Mode right now, time for INO IR Dept. to take the shorts by the throat
My guess now with 5 business days left in June.
1) Phase 1 results
2) Major funding from BARDA or who-ever
3) Start Phase 3 with Military Personnel added
I have GTC Sell Order for 10% of my shares @ $71.00
and 90% of my shares sell GTC set @ $349.00 which may get cancelled by moving it up to ensure Long term Gains...LOL
novio Gets $71M From Pentagon for Vaccine-Delivery Device
Just hit the TheStreet.com
https://www.thestreet.com/investing/inovio-shares-up-as-pentagon-funds-vaccine-delivery-device?puc=yahoo&cm_ven=YAHOO&yptr=yahoo
We just received the cart, the horse is next
Could be one of these 3
1. EUA Emergency Use Authorization
2. Huge BARDA Funding
3. J&J Buyout
Anyone know how many doses of INO-4800 can 900 CELLECTRA 2000 DNA vaccine injection devices can handle. Its just starting, this will be huge when the DOD announces the Vaccine side of this deal for development support.
DOD Awards
Inovio Pharmaceuticals Inc.,* Plymouth Meeting, Pennsylvania, was awarded a $16,570,397 firm-fixed-price contract for 900 CELLECTRA 2000 DNA vaccine injection devices. Bids were solicited via the internet with one received. Work will be performed in Plymouth Meeting, Pennsylvania, with an estimated completion date of Dec. 31, 2020. Fiscal 2020 defense emergency response funds in the amount of $16,570,397 were obligated at the time of the award. U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity (W911QY-20-C-0084). (Awarded June 19, 2020)
https://newsfilter.io/a/c3f3962eb7aa0d903cf5072c166b1e75?fbclid=IwAR2Ix9MpLZoieXUgUVbfuDm7gnPwNvkKjbCCcEyQIZ7l10L8UWnlEIDHnRk
Music can be therapeutic, especially at the end of the month.
More on Kentucky
May 28th
About two months ago, the Alliance for Multispecialty Research (or AMR) told Doctor and researcher Mark Adam’s office in Lexington they could begin studying a potential vaccine.
Around two weeks ago, they learned they would be moving forward.
So far, workers inside his office have gone through training for administering a new vaccine, including a new technique for how to administer it.
So starting next week, they will bring in healthy patients in order to test how this affects them.
Participants will keep diaries detailing their day-to-day feelings and, hopefully, they can call this vaccine a success.
The process is being fast-tracked, it usually takes years.
AMR is seeking healthy patients to participate in this trial with a few groups starting next week.
Anyone interesting in participating can call 859-264-8999.
https://www.q95fm.net/2020/05/28/clinical-trial-for-a-possible-covid-19-vaccine-will-soon-be-at-amr-lexington/
Nice to see you back.
This link to 2 video interviews came out May 27th and both referenced to starting trials the following week which would be the week of June 1st.
This should be the 3rd arm/3rd Located in Lexington.
https://www.wkyt.com/content/news/AMR-Lexington-awarded-COVID-19-vaccine-clinical-trial-570803771.html
Has anyone seen this twitter post about Phase 3
https://charts.stocktwits.com/production/original_221559657.png
Possibly EOD at the close, arranged Buy
According to the last earnings CC May 11th.
Many milestones before August CC….Milestone #1 done…..2nd 3rd and 4th in the next 9 business days????
1st…12 month Overall Survival Efficacy Data from INO-5401 in GBM to be presented to ASCO in late May
2nd…Preliminary safety and immune response data from our U.S. Phase 1 trial for Covid-19 vaccine INO-4800 in 40 healthy volunteers
3rd…Data from our COVID-19 animal challenge studies
4th…Additional External Funding to support INO-4800 development
5th…Either started or be poised to start our large, randomized Phase II/III efficacy trial upon regulatory approval
6th…start of additional clinical trial for INO-4800 in China and in South Korea…..since it appears to only South Korea
7th…start of patient dosing for Phase I/II clinical trial of INO-3107 to treat RRP
J. Joseph Kim, Inovio Pharmaceuticals, Inc. - CEO, President & Director [9]
--------------------------------------------------------------------------------
Thank you, Peter. Before we turn to the analyst Q&A, I'd like to list all of the events we expect before our next earnings report in August. Here are the list: we expect to report on 12 months overall survival efficacy data from INO-5401 in GBM to be presented at ASCO in late May: Second, preliminary safety and immune responses data from our U.S. Phase I trial for COVID-19 vaccine INO-4800 in 40 healthy volunteers; next, data from our COVID-19 animal challenge studies; fourth, additional external funding to support INO-4800 development; fifth, either started or be poised to start our large, randomized Phase II/III efficacy trial upon regulatory approval; sixth, start of additional clinical trial for INO-4800 in China and in South Korea; seventh, start of patient dosing for Phase I/II clinical trial of INO-3107 to treat RRP, a lot of milestones to look forward to.
Now I look forward to taking your questions. Operator, please open the line for the analysts.
================================================================================
Questions and Answers
I hope AdamS007 is still around, Huge news on Phase 1 results within 9
Business Days
AdamS007
Are you still Long this stock?
Have not heard from you in awhile
Another article reporting Dr. John Ervin at Kansas City is testing Inovio COVID-19 vaccine.
https://www.google.com/amp/s/plattecountylandmark.com/2020/06/12/kc-facility-testing-a-covid-19-vaccine/amp/
Using half the dosage immediately doubles the current supply or forecast of promised supply.
I believe this month will have updates on the Kate`s Primate study, the original April 40 participants, Funding, and addition to OWS.
florin d20 hours ago
for those concerned about VGXI and Plasmid DNA read this article: 160 companies worldwide, Richter is mentioned, VGXI is not mentioned. the end point , all this companies want to sell PDNA, INO just have to pick their partner, and Richter is a great one to have. On a personal note, Germans are the best to work with. Everything they do is top notch, they are always on time. https://www.prnewswire.com/news-releases/viral-vectors-and-plasmid-dna-manufacturing-market-2nd-edition-2018-2030-300664807.html
florin d20 hours ago
this is a quote from the article "Prominent examples include (in alphabetical order, no selection criteria) Biovian, BioReliance / SAFC, Cell and Gene Therapy Catapult, Cobra Biologics, FinVector, FUJIFILM Diosynth Biotechnologies, Kaneka Eurogentec, Lonza, MassBiologics, MolMed, Novasep, Oxford BioMedica, Vigene Biosciences and WuXi AppTec.this was in 2018. there are plenty of options there for mass production
florin d…yesterday evening 7:15pm
I did some research trying to find how much it costs to produce NVAX vaccine. they are using a protein part of the virus envelope . This proteins are synthesized or can be used from an inactivated virus. I do believe that NVAX will try to use the cheaper version, which presumes using killed viruses. Nevertheless producing the viral protein is expensive. much more expensive than producing DNA or RNA. this because both DNA or RNA are part of protein synthesis. if they go the synthetic route the price for protein will be astronomic. If they go the killed virus route, they are using the same method China is working at.
SPeaking of China vaccine, they had conflicting results, because they use an adenovirus as a vector and people exposed before to adenovirus( common cold virus) did not responded to vaccine. Needles to say that this is the vaccine AZN and Oxford is working on. Honestly the results are not encouraging at all, and the design of the vaccine is not the greatest exactly for the reason mentioned above. . The downside at using a killed virus is a very short life span for the vaccine efficiency. For this reason NVAX will use their adjuvant matrix, to enhance immune response. Time will tell. Realistically they are at least 2 months behind INO. I attached an article discussing viruses, please observe the comment I made in the past, present in the article, that MODERNA jumped the animal study phase. which is extremely important. The scientific world dropped the jaw, it was really risky what they did, and not well received by the medical world. Also remember that MRNA settled a law suit against them from a bio company. apparently Moderna stole their method of coating RNA with lipids. It is quite sketchy how they develop their products. MODERNA has no product in phase 3, most products phase 1 and only 3 in phase 2. INO has 66% products in phase 2 and 3. so more advanced that MRNA. NVAX has a decent number of products in phase 2 and 3, however they are behind INO in terms of covid vaccine development.
https://blogs.sciencemag.org/pipeline/archives/2020/04/15/coronavirus-vaccine-prospects
https://www.forbes.com/sites/nathanvardi/2017/02/09/mysterious-5-billion-biotech-moderna-hit-with-legal-setback-related-to-key-technology/#4e54750575f7
https://www.statnews.com/2020/05/22/early-study-of-covid-19-vaccine-developed-in-china-sees-mixed-results/
Less
Clinical Trials expanded to 120 participants, Updated June 5
They added group 3 of 80 participants in Kentucky at testing dose of 0.5mg.
Groups 1 & 2 at Pennsylvania and Kansas City had testing dose of 1.0mg and 2.0mg.
Groups 1&2 test results in June, group 3 should be in July.
https://clinicaltrials.gov/ct2/history/NCT04336410?A=3&B=4&C=merged#StudyPageTop
Central Kentucky Research Associates
florin d 20 hours ago
VGXI is a subsidiary of GeneOne Life Science INC. VGXI can ferment in barrels up to 500 liters. Richter Helm can ferment in barrels up to 1500 l.Now we know that INO works with "VGXI, Inc., Richter-Helm, and Ology Biosciences" VGXI is a subsidiary of the GeneOne company from S Korea. All this company can deliver the 1 million doses untill the end of the year. What I see coming from INOVIO is a strong push to scale up DNA plasmid production to the hundreds of millions of doses. They are pushing hard because they know that the vaccine works. I will post the results from MERS vaccine here because those are breathtaking. MERS is a coronavirus almost identical to covid 19( same family). All this to me is very bullish. VGXI is investing heavily to enlarge the DNA plasmid production. INOVIO is way ahead of the game and they want to make sure, when the time is due they have everything ready to kick the mass production. We are months away from those moments, and I see that INOVIO is well positioned, working with great companies. Richter -Helm can produce 3 times more plasmid DNA than VGXI(1500 L barrels versus 500l barrels for VGXI.) I think people are trying to use the news to their advantage, shorts in particular, but the reality is that INO is marching along really well.
I attached here the MERS results so you guys can see how their vaccine for another coronavirus works:
"Overall, for those receiving 0.6 mg of INO-4700, 88% demonstrated
seroconversion after a 2 dose regimen at 0 and 8 weeks, while for those
receiving a 3 dose regimen given at 0, 4 and 12 weeks, 84% seroverted after 2
doses and 100% after 3 doses, as measured by a binding antibody assay against
the full-length S protein (ELISA). Additionally, 92% of the vaccine recipients
in both groups displayed the ability to neutralize the virus using a
neutralization assay (EMC2012-Vero neutralization). Robust T cell responses
were observed in 60% of vaccine recipients after the 2 dose regimen and 84% of
those in the 3 dose group (ELISpot assay). Interestingly, a single dose of 0.6
mg of INO-4700 intradermal vaccination resulted in 74% binding antibody
response rate and 48% neutralization antibody response rate.
Dr. Jerome Kim, Director General of IVI, said, "IVI is pleased to join
partners in reporting these findings as a result of our collaboration in the
world's first vaccine candidate against MERS. These and subsequent clinical
trials could pave the way for accelerated development of a DNA vaccine against
MERS." key words: WORLDS FIRST VACCINE AGAINST MERS" . No company in the covid19vaccine race: MRNA, NVAX,AZN,have the track record INO has.
We operate two GMP-compliant production plants with bioreactor capacities of up to 1500 liters. Richter-Helm consistently works to the highest standards of pharmaceutical quality. This has been verified by major regulatory bodies including EMA, FDA, PMDA, ANVISA, and MFDS as well as by numerous customer audits.")
Another Excellent Post from Florin d on Yahoo
florin d 15 hours ago
cost perspective of PDNA vaccines versus MRNA vaccines. The cost for 1 gram of PDNA varies from 100 to 1000. one dose of vaccine needs about 10 mg, hence the dose price can go from 1 dollar to 10 dollars. for MRNA the price is 1.5 dollars per microgram. A dose of vaccine needs 25-30 micrograms .This is 45 dollars per dose. This is because in order to produce MRNA from a PDNA there are multiple other steps that are technology intensive, hence expensive. Right off the bat we see where the price advantage sits in the future covid vaccine. For MODERNA to bring the price in the range of 10 dollars, honestly I have huge doubts they can do it. Reason number 1 is that they produce their material in SWISS. One of the most expensive country to produce anything. But I hope they can do it, although I doubt it.
Another issue is efficiency. Even if that MRNA can induce antibodies, we dont know if those are neutralizing antibodies, and we dont know how long they last. For example, if they last 3 months, no one will buy the vaccine. It must hold the antibody titer for years. Fortunately we know that INO on prior test with MERS 4700 vaccine, they have long lasting titer"similar to people recovering from disease".
In terms of the VGIX and the IP for the production process. There is a large number of companies producing PDNA . I found so many of them producing about 100 grams of PDNA, which is about 10 000 vaccines. All of them have certification, they dont need any IP process and so on. All they need is the gene sequence and they produce it. For this reason, to me its quite clear that VGXI issue is truly minor. They have strong competition, and those companies would take INOVIO money right away. they can offer PDNA at an average cost of 5 dollars per 10 mg.( vaccine dose). I am sure that in large quantities the price might come down even more.
As a final conclusion INO PDNA vaccine is cheaper, yelding better results than MRNA and there are plenty of plasmid producers competing with each other. Lets wait for INO4800 results, and in a logical fashion it should replicate INO4700 results, which were outsanding, generating immunity similar to people that healed from disease. This is what I could find, I hope it will help you guys see through the BS published here, and make you feel better about your support for INO.